Biotechnology
Compare Stocks
2 / 10Stock Comparison
TVGN vs IMVT
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
TVGN vs IMVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $1.48B | $5.53B |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-31M | $-464M |
| Total Debt | $3M | $98K |
| Cash & Equiv. | $1M | $714M |
TVGN vs IMVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jan 22 | May 26 | Return |
|---|---|---|---|
| Tevogen Bio Holding… (TVGN) | 100 | 1.5 | -98.5% |
| Immunovant, Inc. (IMVT) | 100 | 389.4 | +289.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: TVGN vs IMVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
TVGN is the clearest fit if your priority is growth exposure.
- EPS growth 47.6%
IMVT carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 1.37
- 173.6% 10Y total return vs TVGN's -98.5%
- Lower volatility, beta 1.37, Low D/E 0.0%, current ratio 11.16x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | -21.3% revenue growth vs TVGN's -6.7% | |
| Quality / Margins | 3.2% margin vs TVGN's -5.3% | |
| Stability / Safety | Beta 1.37 vs TVGN's 2.02 | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +96.1% vs TVGN's -85.6% | |
| Efficiency (ROA) | -44.1% ROA vs TVGN's -6.9% |
TVGN vs IMVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
IMVT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
TVGN and IMVT operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$30M | -$487M |
| Net IncomeAfter-tax profit | -$31M | -$464M |
| Free Cash FlowCash after capex | -$13M | -$423M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +13.5% | +19.7% |
Valuation Metrics
TVGN leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $1.5B | $5.5B |
| Enterprise ValueMkt cap + debt − cash | $1.5B | $4.8B |
| Trailing P/EPrice ÷ TTM EPS | -79.91x | -9.97x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | — | 5.83x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
IMVT leads this category, winning 3 of 4 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), TVGN scores 4/9 vs IMVT's 2/9, reflecting mixed financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | — | -47.1% |
| ROA (TTM)Return on assets | -6.9% | -44.1% |
| ROICReturn on invested capital | — | — |
| ROCEReturn on capital employed | — | -66.1% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 2 |
| Debt / EquityFinancial leverage | — | 0.00x |
| Net DebtTotal debt minus cash | $2M | -$714M |
| Cash & Equiv.Liquid assets | $1M | $714M |
| Total DebtShort + long-term debt | $3M | $98,000 |
| Interest CoverageEBIT ÷ Interest expense | -219.56x | — |
Total Returns (Dividends Reinvested)
IMVT leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IMVT five years ago would be worth $16,241 today (with dividends reinvested), compared to $151 for TVGN. Over the past 12 months, IMVT leads with a +96.1% total return vs TVGN's -85.6%. The 3-year compound annual growth rate (CAGR) favors IMVT at 12.1% vs TVGN's -76.0% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -58.9% | +5.1% |
| 1-Year ReturnPast 12 months | -85.6% | +96.1% |
| 3-Year ReturnCumulative with dividends | -98.6% | +40.9% |
| 5-Year ReturnCumulative with dividends | -98.5% | +62.4% |
| 10-Year ReturnCumulative with dividends | -98.5% | +173.6% |
| CAGR (3Y)Annualised 3-year return | -76.0% | +12.1% |
Risk & Volatility
IMVT leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
IMVT is the less volatile stock with a 1.37 beta — it tends to amplify market swings less than TVGN's 2.02 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IMVT currently trades 90.5% from its 52-week high vs TVGN's 9.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.02x | 1.37x |
| 52-Week HighHighest price in past year | $75.50 | $30.09 |
| 52-Week LowLowest price in past year | $0.35 | $13.36 |
| % of 52W HighCurrent price vs 52-week peak | +9.9% | +90.5% |
| RSI (14)Momentum oscillator 0–100 | 53.8 | 60.2 |
| Avg Volume (50D)Average daily shares traded | 34K | 1.4M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates TVGN as "Hold" and IMVT as "Buy".
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy |
| Price TargetConsensus 12-month target | — | $45.50 |
| # AnalystsCovering analysts | 1 | 23 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
IMVT leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). TVGN leads in 1 (Valuation Metrics).
TVGN vs IMVT: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is TVGN or IMVT a better buy right now?
Analysts rate Immunovant, Inc.
(IMVT) a "Buy" — based on 23 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — TVGN or IMVT?
Over the past 5 years, Immunovant, Inc.
(IMVT) delivered a total return of +62. 4%, compared to -98. 5% for Tevogen Bio Holdings Inc. (TVGN). Over 10 years, the gap is even starker: IMVT returned +173. 6% versus TVGN's -98. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — TVGN or IMVT?
By beta (market sensitivity over 5 years), Immunovant, Inc.
(IMVT) is the lower-risk stock at 1. 37β versus Tevogen Bio Holdings Inc. 's 2. 02β — meaning TVGN is approximately 47% more volatile than IMVT relative to the S&P 500.
04Which has better profit margins — TVGN or IMVT?
Tevogen Bio Holdings Inc.
(TVGN) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Immunovant, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TVGN leads at 0. 0% versus 0. 0% for IMVT. At the gross margin level — before operating expenses — TVGN leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — TVGN or IMVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is TVGN or IMVT better for a retirement portfolio?
For long-horizon retirement investors, Immunovant, Inc.
(IMVT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+173. 6% 10Y return). Tevogen Bio Holdings Inc. (TVGN) carries a higher beta of 2. 02 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (IMVT: +173. 6%, TVGN: -98. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between TVGN and IMVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.